成人2型糖尿病的诊断与治疗:综述
本综述总结成人2型糖尿病的诊断与治疗。诊断阈值为空腹血糖≥126 mg/dL、HbA1c≥6.5%或75g口服葡萄糖耐量试验2小时血糖≥200 mg/dL。治疗包括生活方式(饮食、运动、体重管理)和二甲双胍作为一般一线;合并心血管或肾脏疾病或高心血管风险者,指南推荐早期使用SGLT2i和/或GLP-1RA。强化降糖(HbA1c<7%)在试验完成2年后绝对减少微血管病3.5%、心肌梗死3.3%-6.2%、死亡2.7%-4.9%;特定SGLT2i和GLP-1RA在2-5年内减少动脉粥样硬化性心血管疾病风险12%-26%、心力衰竭18%-25%、肾脏疾病24%-39%。
要点
- 诊断标准:空腹血糖≥126 mg/dL、HbA1c≥6.5%或75g口服葡萄糖耐量试验2小时血糖≥200 mg/dL。
- 合并心血管或肾脏疾病或高心血管风险者,指南推荐早期使用SGLT2i和/或GLP-1RA。
- 特定SGLT2i和GLP-1RA在2-5年内减少动脉粥样硬化性心血管疾病风险12%-26%、心力衰竭18%-25%、肾脏疾病24%-39%。
- 强化降糖(HbA1c<7%)在试验完成2年后绝对减少微血管病3.5%、心肌梗死3.3%-6.2%、死亡2.7%-4.9%。
- 高 potency GLP-1RA 和双 GIP/GLP-1RA 使多数2型糖尿病患者体重下降>5%,体重下降可能超过10%。
适用人群与场景
- 成人2型糖尿病患者;风险因素包括年龄较大、家族史、超重或肥胖、缺乏体力活动、妊娠糖尿病、西班牙裔、美洲印第安人或阿拉斯加原住民、亚洲人或黑人种族。
- 约三分之一2型糖尿病成人合并心血管疾病,10.1%有严重视力困难或失明;肾衰竭患者中2型糖尿病患病率为39.2%。
诊断标准与关键阈值
- 空腹血浆葡萄糖≥126 mg/dL。
- 血红蛋白A1C≥6.5%。
- 75-g口服葡萄糖耐量试验2小时血糖≥200 mg/dL。
处置流程与药物剂量
- 生活方式干预包括饮食、运动和体重管理;没有特定饮食被证明对改善健康结局最有效。
- 二甲双胍通常为一线治疗以达到血红蛋白A1C目标。
- 合并心血管或肾脏疾病或高心血管风险者,指南推荐早期使用SGLT2i和/或GLP-1RA。
- 常见附加药物包括双GIP/GLP-1RA、二肽基肽酶-4抑制剂、磺脲类和噻唑烷二酮类。
- 约三分之一2型糖尿病患者一生中需要胰岛素治疗。
- 体力活动可降低血红蛋白A1C 0.4%至1.0%并改善心血管风险因素(即高血压和血脂异常)。
研究设计与关键结果
- 本综述汇总证据:强化降糖策略(血红蛋白A1C<7%)对比常规治疗,在试验完成2年后绝对减少微血管病3.5%(如视网膜病变和肾病)、心肌梗死3.3%-6.2%、死亡2.7%-4.9%。
- 特定SGLT2i和GLP-1RA对比安慰剂在2至5年内减少动脉粥样硬化性心血管疾病风险12%-26%、心力衰竭风险18%-25%、肾脏疾病风险24%-39%;大多数试验参与者正在服用二甲双胍。
- 高 potency GLP-1RA 和双 GIP/GLP-1RA 使多数2型糖尿病患者体重下降>5%,体重下降可能超过10%。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对2型糖尿病成人,二甲双胍通常为一线治疗以达到血红蛋白A1C目标,同时进行生活方式干预(饮食、运动和体重管理)。
- 对合并心血管或肾脏疾病或高心血管风险的2型糖尿病个体,指南推荐早期使用SGLT2i和/或GLP-1RA。
- 体力活动可降低血红蛋白A1C 0.4%至1.0%并改善心血管风险因素(即高血压和血脂异常)。
- 高 potency GLP-1RA 和双 GIP/GLP-1RA 可使多数2型糖尿病患者体重下降>5%,体重下降可能超过10%。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Type 2 diabetes involves progressive loss of insulin secretion from pancreatic β cells in the setting of insulin resistance and manifests clinically as hyperglycemia. Type 2 diabetes accounts for 90% to 95% of all cases of diabetes globally, with estimates ranging from 589 million to 828 million people worldwide. In the US, type 2 diabetes affects approximately 1 in 6 adults.
OBSERVATIONS: Risk factors for type 2 diabetes include older age, family history, overweight or obesity, physical inactivity, gestational diabetes, Hispanic ethnicity, and American Indian or Alaska Native, Asian, or Black race. Diabetes is diagnosed if fasting plasma glucose is greater than or equal to 126 mg/dL, hemoglobin A1C is greater than or equal to 6.5%, or 2-hour glucose during 75-g oral glucose tolerance testing is greater than or equal to 200 mg/dL. Approximately one-third of adults with type 2 diabetes have cardiovascular disease and 10.1% have severe vision difficulty or blindness. The prevalence of type 2 diabetes is 39.2% among patients with kidney failure. Although weight management is an important component of treatment for type 2 diabetes, no specific diet has been proven to be most effective for improving health outcomes. Physical activity can reduce hemoglobin A1C by 0.4% to 1.0% and improve cardiovascular risk factors (ie, hypertension and dyslipidemia). Randomized clinical trials have reported absolute reductions in microvascular disease (3.5%), such as retinopathy and nephropathy, myocardial infarction (3.3%-6.2%), and mortality (2.7%-4.9%), with intensive glucose-lowering strategies (hemoglobin A1C <7%) vs conventional treatment 2 decades after trial completion. First-line medications for type 2 diabetes include metformin and, in patients with cardiovascular or kidney comorbidities or at high cardiovascular risk, glucagon-like peptide-1 receptor agonists (GLP-1RAs) or sodium-glucose cotransporter 2 inhibitors (SGLT2is). Common add-on medications include dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs, dipeptidyl peptidase-4 inhibitors, sulfonylureas, and thiazolidinediones. Approximately one-third of patients with type 2 diabetes require treatment with insulin during their lifetime. Several randomized clinical trials have demonstrated benefits of specific SGLT2i and GLP-1RA medications compared with placebo for atherosclerotic cardiovascular disease (12%-26% risk reduction), heart failure (18%-25% risk reduction), and kidney disease (24%-39% risk reduction) over 2 to 5 years. Most trial participants with type 2 diabetes were taking metformin. High-potency GLP-1RA and dual GIP/GLP-1RA medications result in weight loss of greater than 5% in most individuals with type 2 diabetes, and weight loss may exceed 10%.
CONCLUSIONS: Type 2 diabetes affects up to 14% of the global population and is associated with preventable long-term complications, such as cardiovascular disease, kidney failure, vision loss, and increased mortality. In addition to lifestyle modifications including diet, exercise, and weight management, metformin is generally first-line therapy for attainment of hemoglobin A1C targets. For individuals with type 2 diabetes and cardiovascular or kidney disease or at high cardiovascular risk, guidelines recommend early treatment with SGLT2i and/or GLP-1RA medications.
参考来源
- Kalyani RR, Neumiller JJ, Maruthur NM, et al. Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review. JAMA. 2025. PMID: 40549398. doi:10.1001/jama.2025.5956
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。